Jun 2026 (Q2 FY26) — Jul 28, 2026
NeoGenomics Q2 FY26 — Strong Clinical Growth and Margin Expansion Drive Raised Guidance
Read the full callNeoGenomics (NEO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
NeoGenomics earnings: last reported Tue, 28 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 202 | +11.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -4.8 | +21.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$16.42 −1.38% · −$0.23
Performance +63.4% 1Y
1Y: $10.05 on 17 Oct 2025 → $16.42. High $19.91 (18 Sept 2026), low $7.19 (27 Mar 2026).
- Previous close
- $16.65
- 52-week range
- $7.19 – $19.91
- One year
- +55.05%
Overview
- Symbol
- NEO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
NeoGenomics earnings calls (NEO)
Financials
What the filings say
Net profit, year on year: +105% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 168 | 172 | 168 | 181 | 188 | 190 | 187 | 202 |
| Operating profit | -21 | -18 | -28 | -48 | -27 | -13 | -18 | -10 |
| Operating margin | −12.6% | −10.7% | −16.6% | −26.3% | −14.4% | −7.0% | −9.8% | −4.8% |
| Interest | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | — | 0 | — | 0 | — | 0 | — |
| Profit before tax | -18 | -16 | -26 | -46 | -26 | -12 | -18 | 2 |
| Tax rate | 0.8% | 5.0% | −1.0% | 1.6% | −2.8% | 20.4% | 2.7% | −22.6% |
| Net profit | -18 | -15 | -26 | -45 | -27 | -10 | -17 | 2 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -19 | -11 | -7 | -15 | -159 | -247 | -326 | -434 |
| Total liabilities | 185 | 202 | 294 | 762 | 742 | 740 | 736 | 523 |
| Fixed assets | 61 | 64 | 86 | 109 | 102 | 92 | 94 | 85 |
| Total assets | 505 | 710 | 988 | 1,870 | 1,740 | 1,681 | 1,638 | 1,360 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 45 | 23 | 1 | -27 | -66 | -2 | 7 | 5 |
| Cash from investing | -140 | -20 | -159 | -632 | 1 | 77 | 13 | -12 |
| Cash from financing | 92 | 159 | 236 | 725 | 12 | 5 | 5 | -200 |
| Net cash flow | -3 | 163 | 78 | — | — | — | — | — |
| Capital expenditure | -14 | -20 | -29 | -64 | -31 | -29 | -41 | -27 |
| Free cash flow | 30 | 3 | -28 | -91 | -97 | -31 | -34 | -22 |
Insider filings
53 filings between Nov 25, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$967.9K
5 sales by 4 insiders
80% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 26
- Option exercise — converted options into shares
- 22
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Aunan Greg D | — | $321.4K | Aug 4, 2026 |
| Stone Warren | — | $276.7K | Jan 20, 2026 |
| Olivo Alicia C | — | $251.0K | Nov 25, 2025 |
| TETRAULT LYNN A. | — | $118.8K | Jun 15, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 17,562 | $0 |
| Oct 1, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 6,911 | $0 |
| Sep 1, 2026 | Olivo Alicia C EVP, GC & Business Development | Tax withheld | 2,692 | $0 |
| Aug 21, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 28,106 | $0 |
| Aug 21, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 11,060 | $0 |
| Aug 4, 2026 | Aunan Greg D Chief Accounting Officer | Sale | 20,000 | $321.4K |
| Jun 15, 2026 | TETRAULT LYNN A. Director | Sale 10b5-1 plan | 5,307 | $58.9K |
| Jun 9, 2026 | TETRAULT LYNN A. Director | Sale 10b5-1 plan | 5,307 | $59.9K |
| Jun 1, 2026 | Perez David Brian Director | Option exercise | 23,077 | $0 |
| Jun 1, 2026 | Kelly Michael Aaron Director | Option exercise | 23,077 | $0 |
| Jun 1, 2026 | KANOVSKY STEPHEN M Director | Option exercise | 23,077 | $0 |
| Jun 1, 2026 | Kenny John P. Director | Option exercise | 5,893 | $0 |
| Jun 1, 2026 | Williams Felicia Director | Option exercise | 23,077 | $0 |
| Jun 1, 2026 | TETRAULT LYNN A. Director | Option exercise | 23,077 | $0 |
| Jun 1, 2026 | Gunn Neil Director | Option exercise | 23,077 | $0 |
| Jun 1, 2026 | Green Marjorie C Director | Option exercise | 22,964 | $0 |
| May 11, 2026 | Olivo Alicia C EVP, GC & Business Development | Tax withheld | 2,559 | $0 |
| May 11, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 3,783 | $0 |
| May 11, 2026 | Olivo Alicia C EVP, GC & Business Development | Option exercise | 3,944 | $0 |
| May 11, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 5,830 | $0 |
| May 2, 2026 | Aunan Greg D Chief Accounting Officer | Tax withheld | 1,309 | $0 |
| May 2, 2026 | Aunan Greg D Chief Accounting Officer | Option exercise | 5,372 | $0 |
| May 2, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 5,969 | $0 |
| May 2, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 2,349 | $0 |
| May 1, 2026 | Olivo Alicia C EVP, GC & Business Development | Tax withheld | 1,042 | $0 |
| May 1, 2026 | Aunan Greg D Chief Accounting Officer | Tax withheld | 937 | $0 |
| Apr 1, 2026 | Zook Anthony P. Chief Executive Officer | Option exercise | 140,498 | $0 |
| Apr 1, 2026 | Zook Anthony P. Chief Executive Officer | Tax withheld | 45,453 | $0 |
| Apr 1, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 6,911 | $0 |
| Apr 1, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 17,562 | $0 |
| Feb 23, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 3,323 | $0 |
| Feb 23, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 8,443 | $0 |
| Feb 23, 2026 | Sherman Jeffrey Scott Chief Financial Officer | Tax withheld | 3,783 | $0 |
| Feb 23, 2026 | Sherman Jeffrey Scott Chief Financial Officer | Option exercise | 15,535 | $0 |
| Feb 23, 2026 | Olivo Alicia C EVP, GC & Business Development | Tax withheld | 3,323 | $0 |
| Feb 23, 2026 | Olivo Alicia C EVP, GC & Business Development | Option exercise | 8,443 | $0 |
| Feb 21, 2026 | Olivo Alicia C EVP, GC & Business Development | Option exercise | 21,079 | $0 |
| Feb 21, 2026 | Aunan Greg D Chief Accounting Officer | Tax withheld | 1,875 | $0 |
| Feb 21, 2026 | Aunan Greg D Chief Accounting Officer | Option exercise | 6,323 | $0 |
| Feb 21, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 7,142 | $0 |
| Feb 21, 2026 | Olivo Alicia C EVP, GC & Business Development | Tax withheld | 8,295 | $0 |
| Feb 21, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 28,105 | $0 |
| Feb 21, 2026 | Sherman Jeffrey Scott Chief Financial Officer | Tax withheld | 10,729 | $0 |
| Feb 21, 2026 | Sherman Jeffrey Scott Chief Financial Officer | Option exercise | 42,158 | $0 |
| Jan 20, 2026 | Stone Warren Pres & Chief Operating Officer | Sale 10b5-1 plan | 22,128 | $276.7K |
| Jan 13, 2026 | Stone Warren Pres & Chief Operating Officer | Tax withheld | 15,127 | $0 |
| Jan 13, 2026 | Stone Warren Pres & Chief Operating Officer | Option exercise | 59,382 | $0 |
| Jan 13, 2026 | Olivo Alicia C EVP, GC & Business Development | Tax withheld | 15,145 | $0 |
| Jan 13, 2026 | Olivo Alicia C EVP, GC & Business Development | Option exercise | 59,382 | $0 |
| Dec 7, 2025 | Sherman Jeffrey Scott Chief Financial Officer | Tax withheld | 11,938 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NEOGENOMICS INC
Free account. Everything above stays public.
Write why you follow NEOGENOMICS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading